A neuraminidase-targeted nanobody confers broad protection against influenza B virus
The identification of VHH5, a nanobody targeting conserved residues within the neuraminidase active site of the influenza B virus, conferring broad inhibitory activity is reported, establishing VHH5-Fc as a promising therapeutic candidate with potent and broad-spectrum activity against antigenically diverse IBV strains...